

Recombinant Human Mesothelin/MSLN (C-His)

Catalog No: BP048

Description	Recombinant Human Mesothelin is produced by Human 293 Cells. The target gene encoding E296-D580 is expressed with a 10His tag at the C terminus.
Expression System	Human cells
Alternative name	Megakaryocyte potentiating factor; mesothelin; Pre-pro-megakaryocyte-potentiating factor;soluble MPF mesothelin related protein; CAK1; MPF; MSLN; SMR; CAK1; CAK1 antigen
Accession No.	Q13421
Predicted Molecular Weight	37.6kDa
Apparent Molecular Weight	35-45kDa, reducing conditions.
Quality Control	Purity: greater than 95% as determined by reducing SDS-PAGE. Endotoxin: less than 0.1 ng/μg (1 EU/μg) as determined by TAL test.
Formulation	PBS, pH 7.4
Reconstitution	It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below.
Storage	Lyophilized protein should be stored at < -20°C, though stable at room temperature for 3 weeks. Reconstituted protein solution can be stored at 4-7°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months. Always centrifuge tubes before opening. Do not mix by vortex or pipetting.
Background	Mesothelin (MSLN) is a cell surface glycoprotein that belongs to the mesothelin family. It can be expressed by mesothelial cells of the serosa (pleura, pericardium, and peritoneum) and epithelial cells of the trachea, tonsils, fallopian tube, and kidneys. The Membrane-anchored form of mesothelin may play a role in cellular adhesion. Mesothelin is also found highly expressed in various cancers, including malignant mesothelioma, pancreatic or ovarian carcinoma, sarcomas and in some gastrointestinal or pulmonary carcinomas. Due to its limited expression in normal tissues, mesothelin has been reported as an ideal tumor-associated marker for the development of targeted therapy.

SDS-PAGE

